EC
MRNS

EntryPoint Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

EntryPoint Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,574
Closed -$50.4K – 1765
2024
Q1 		$50.4K Buy
+5,574
New +$54.2K 0.05% 761

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EntryPoint Capital's MRNS Position: Q2 2024 in Review

EntryPoint Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 5,574 shares — an estimated $50.4K sold.

EntryPoint Capital first reported a position in MRNS in Q1 2024 and held it in 1 quarter. The position peaked at $50.4K in Q1 2024. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • EntryPoint Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 5,574 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $50.4K.
  • EntryPoint Capital first reported a position in Marinus Pharmaceuticals, Inc in Q1 2024 and held it in 1 quarter.
  • EntryPoint Capital's Marinus Pharmaceuticals, Inc position peaked at $50.4K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.